SCHEMBL25166115

SCHEMBL25166115

BC1=CCN(C(=O)OC(C)(C)C)C(C)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PREP P48147 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
NPC1 O15118 2/20 0.34
UCHL1 P09936 1/20 0.34
GPR119 Q8TDV5 2/20 0.34
ELANE P08246 1/20 0.34
RAB9A P51151 1/20 0.34
GRM5 P41594 3/20 0.34
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21276535 0.76 MAPK1 (0.39) PREPCHRM2CHRM1CHRM3NPC1
SCHEMBL25166086 0.75 USP30 (0.38) PREPNPC1UCHL1GPR119GRM5
SCHEMBL31457954 0.74 GPR119 (0.35) CHRM2CHRM1CHRM3NPC1GPR119
SCHEMBL12069963 0.73 PDK4 (0.50) GRM5PDK4
SCHEMBL19390105 0.73 CHRM2 (0.38) CHRM2CHRM1CHRM3ELANEHSD17B10
SCHEMBL23415868 0.73 CHRM2 (0.38) CHRM2CHRM1CHRM3ELANEHSD17B10
SCHEMBL17409654 0.73 PREP (0.43) PREPCHRM2CHRM1CHRM3NPC1
SCHEMBL24700152 0.72 GRM5 (0.42) UCHL1GPR119GRM5PDK4
SCHEMBL18198355 0.72 SETD7 (0.39) PREPCHRM2CHRM1CHRM3NPC1
SCHEMBL4175218 0.71 CHRM2 (0.44) PREPCHRM2CHRM1CHRM3GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed